CLX · Clorox Co /De/
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBIT non-GAAP | $1.03B | Twelve months ended June 30, 2026 | — |
| Adjusted EBIT margin non-GAAP | 15.3% | Twelve months ended June 30, 2026 | — |
| Adjusted EPS non-GAAP | $5.53 | Twelve months ended June 30, 2026 | — |
|
|
|||
| Adjusted free cash flow non-GAAP | $881M | Fiscal year 2026 | — |
| Free cash flow as a percentage of net sales non-GAAP | 13.1% | Fiscal year 2026 | — |
| Organic sales growth / (decrease) (non-GAAP) non-GAAP | -13% | Three months ended June 30, 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Net sales growth / (decrease) (GAAP) -2%
-1% Foreign Exchange
-10% Divestitures/Acquisitions
= Organic sales growth / (decrease) (non-GAAP) -13%
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Household & Personal Products — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CLX
this stock
Clorox Co /De/
|
$12.98B | +5.2% | +2.5% | 17.4 | 11.2% |
|
PG
PROCTER & GAMBLE Co
|
$335.60B | -0.2% | +3.3% | 21.8 | 1.2% |
|
UL
Unilever PLC
|
$136.52B | -3.1% | — | — | 0.1% |
|
CL
Colgate Palmolive Co
|
$72.90B | +13.5% | +1.7% | 36.2 | 2.2% |
|
RBGLY
Reckitt Benckiser Group PLC
|
$43.52B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CLX | -0.5% | +13.1% | -16.6% | +11.0% | +5.2% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +1.5% | +9.7% | -27.8% | +8.9% | -6.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.